Candice Meyzer1, Pierre Frange, Hélène Chappuy, Blandine Desse, Florence Veber, Hervé Le Clésiau, Gérard Friedlander, Stéphane Blanche, Jean-Claude Souberbielle, Jean-Marc Tréluyer, Marie Courbebaisse. 1. From the *Unité de Recherche Clinique Paris Centre, Hôpital Necker Enfants Malades, Assistance Publique Hôpitaux de Paris; †CIC P0901 Mère Enfant, Inserm, Hôpital Necker Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris Descartes; ‡EA3620, Université Paris Descartes, Sorbonne Paris-Cité; §Unité d'Immunologie et Hématologie Pédiatriques; ¶Urgences Pédiatriques, Hôpital Necker Enfants Malades, Assistance Publique Hôpitaux de Paris; ‖Laboratoire d'Ethique Médicale, Université Paris Descartes, Paris; **Centre d'Examens de Santé de la Caisse Primaire d'Assurance Maladie de la Seine-Saint-Denis, Bobigny; ††Service d'Explorations Fonctionnelles, Hôpital Necker Enfants Malades, Assistance Publique Hôpitaux de Paris; ‡‡INSERM U845, équipe Homéostasie du Phosphate, Université Paris Descartes; §§Pharmacologie, Groupe Hospitalier Broca Cochin Hôtel Dieu; and ¶¶Service de Physiologie et Explorations Fonctionnelles, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, Paris, France.J.-M.T. and M.C. contributed equally to the study.
Abstract
BACKGROUND: Vitamin D insufficiency and HIV infection are both risk factors for chronic disorders, so it is important to consider vitamin D status in HIV-infected patients. METHODS: We prospectively investigated serum 25-hydroxyvitamin D (25(OH)D) concentrations, determined by radioimmunoassay, in 113 HIV-infected children (age≤24 years) and 54 healthy controls matched for age and phototype. We assessed the prevalence of vitamin D deficiency and insufficiency (VDD and VDI) defined as 25(OH)D titers of <10 ng/mL and between 10 and 30 ng/mL, respectively, and their predictive factors. RESULTS: The overall prevalence of VDD and VDI was 38.9% and 58.7%, respectively. Mean serum 25(OH)D concentrations were significantly higher in the HIV group than the control group (14.2±6.9 ng/mL vs. 10.4±5 ng/mL, P<0.001). Variables significantly associated with low serum 25(OH)D concentrations in HIV-infected children were dark phototype (P<0.001) and age (r=-0.19, P=0.03). Patients receiving efavirenz had a trend toward lower serum 25(OH)D concentrations (11.1±4.6 ng/mL vs. 14.6±7 ng/mL, P=0.1). Dark phototype was the only independent risk factor for VDD in HIV-infected children (odds ratio=14.6; 95% confidence interval: 2.4-89.9, P=0.004). CONCLUSIONS: VDD and VDI were common in both HIV-infected and control groups, and serum 25(OH)D concentrations were significantly lower in controls than in HIV-infected children.
BACKGROUND:Vitamin Dinsufficiency and HIV infection are both risk factors for chronic disorders, so it is important to consider vitamin D status in HIV-infectedpatients. METHODS: We prospectively investigated serum 25-hydroxyvitamin D (25(OH)D) concentrations, determined by radioimmunoassay, in 113 HIV-infectedchildren (age≤24 years) and 54 healthy controls matched for age and phototype. We assessed the prevalence of vitamin Ddeficiency and insufficiency (VDD and VDI) defined as 25(OH)D titers of <10 ng/mL and between 10 and 30 ng/mL, respectively, and their predictive factors. RESULTS: The overall prevalence of VDD and VDI was 38.9% and 58.7%, respectively. Mean serum 25(OH)D concentrations were significantly higher in the HIV group than the control group (14.2±6.9 ng/mL vs. 10.4±5 ng/mL, P<0.001). Variables significantly associated with low serum 25(OH)D concentrations in HIV-infectedchildren were dark phototype (P<0.001) and age (r=-0.19, P=0.03). Patients receiving efavirenz had a trend toward lower serum 25(OH)D concentrations (11.1±4.6 ng/mL vs. 14.6±7 ng/mL, P=0.1). Dark phototype was the only independent risk factor for VDD in HIV-infectedchildren (odds ratio=14.6; 95% confidence interval: 2.4-89.9, P=0.004). CONCLUSIONS: VDD and VDI were common in both HIV-infected and control groups, and serum 25(OH)D concentrations were significantly lower in controls than in HIV-infectedchildren.
Authors: Giuseppe Saggese; Francesco Vierucci; Flavia Prodam; Fabio Cardinale; Irene Cetin; Elena Chiappini; Gian Luigi De' Angelis; Maddalena Massari; Emanuele Miraglia Del Giudice; Michele Miraglia Del Giudice; Diego Peroni; Luigi Terracciano; Rino Agostiniani; Domenico Careddu; Daniele Giovanni Ghiglioni; Gianni Bona; Giuseppe Di Mauro; Giovanni Corsello Journal: Ital J Pediatr Date: 2018-05-08 Impact factor: 2.638
Authors: Virginia A Stallings; Joan I Schall; Mary L Hediger; Babette S Zemel; Florin Tuluc; Kelly A Dougherty; Julia L Samuel; Richard M Rutstein Journal: Pediatr Infect Dis J Date: 2015-02 Impact factor: 2.129
Authors: Aylin B Unsal; Aviva S Mattingly; Sara E Jones; Julia B Purdy; James C Reynolds; Jeffrey B Kopp; Rohan Hazra; Colleen M Hadigan Journal: J Clin Endocrinol Metab Date: 2017-08-01 Impact factor: 5.958
Authors: Kelly A Dougherty; Joan I Schall; Babette S Zemel; Florin Tuluc; Xiaoling Hou; Richard M Rutstein; Virginia A Stallings Journal: J Pediatric Infect Dis Soc Date: 2014-03-27 Impact factor: 3.164
Authors: Long Zhang; Adrienne Tin; Todd T Brown; Joseph B Margolick; Mallory D Witt; Frank J Palella; Lawrence A Kingsley; Andrew N Hoofnagle; Lisa P Jacobson; Alison G Abraham Journal: AIDS Res Hum Retroviruses Date: 2016-11-17 Impact factor: 2.205
Authors: Andrew P Steenhoff; Joan I Schall; Julia Samuel; Boitshepo Seme; Marape Marape; Bakgaki Ratshaa; Irene Goercke; Michael Tolle; Maria S Nnyepi; Loeto Mazhani; Babette S Zemel; Richard M Rutstein; Virginia A Stallings Journal: PLoS One Date: 2015-02-23 Impact factor: 3.240